TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33942327

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT), median volume of 828 ml (range: 817–960), administered 14 days after ICU admission.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 14
Study: 34930267

Group type: EXPERIMENTAL
Intervention: Cipargamin (10 to 150 mg single doses and 10 to 50 mg once daily for 3 days)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Artemether–lumefantrine (control)
Number of subjects: 186
Study: 32527382

Group type: EXPERIMENTAL
Intervention: Primary care treatment
Number of subjects: 288

Group type: COMPARATOR
Intervention: Specialist outpatient care
Number of subjects: 288
Study: 34358491

Group type: EXPERIMENTAL
Intervention: Whole body hypothermia (33·5°C) for 72 h
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 408
Study: 33250082

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% QD
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% BID
Number of subjects: 386

Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 386
Study: 36394727

Group type: EXPERIMENTAL
Intervention: MIRE exposure and Tai Chi exercise (30 min MIRE + 40-45 min Tai Chi, 3 sessions/week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham group (Tai Chi exercise only)
Number of subjects: 49
Study: 34859493

Group type: EXPERIMENTAL
Intervention: Mevidalen 10 mg
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Mevidalen 30 mg
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Mevidalen 75 mg
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 32662327

Group type: EXPERIMENTAL
Intervention: Sit-stand workstations (Group 1: 40:20, n=8; Group 2: 30:30, n=6; Group 3: 20:40, n=7)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (usual sitting, n=11)
Number of subjects: 32
Study: 33523774

Group type: EXPERIMENTAL
Intervention: Budesonide intranasal formulation with charcoal block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide intranasal formulation without charcoal block
Number of subjects: 0
Study: 32073622

Group type: EXPERIMENTAL
Intervention: Manual pill counting using a plastic dish and spatula
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Efforts put into pill counting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Interventions alleviating the burden of pill counting
Number of subjects: 44
Study: 33673587

Group type: EXPERIMENTAL
Intervention: Almonds (20% of daily energy consumption)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calorie-matched snack (control)
Number of subjects: 100
Study: 32391667

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg per day for 5 days plus conventional treatments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 30
Study: 35579297

Group type: EXPERIMENTAL
Intervention: Normal saline infusion at a rate of 125 mL/h
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 1/3-2/3 infusion at a rate of 125 mL/h
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion at a rate of 125 mL/h
Number of subjects: 450

Group type: COMPARATOR
Intervention: All groups (Normal saline, 1/3-2/3, Ringer's lactate)
Number of subjects: 450
Study: 34869172

Group type: EXPERIMENTAL
Intervention: Multi-media training on HIV-related stigma
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (teachers without training)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Adolescents living with HIV
Number of subjects: 330
Study: 36096824

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (350 mg elemental magnesium/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Phosphate binder sucroferric oxyhydroxide (1000 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Magnesium citrate + Phosphate binder
Number of subjects: 180
Study: 33979464

Group type: EXPERIMENTAL
Intervention: Xiyanping injection in combination with standard therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard supportive therapy alone
Number of subjects: 130
Study: 34288256

Group type: EXPERIMENTAL
Intervention: OneCurve only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OneG and OneCurve
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OneFlare and OneCurve
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OneFlare, OneG, and OneCurve
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glide-path preparation
Number of subjects: 60
Study: 34485157

Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion of anti‐angiogenic therapy plus CCRT
Number of subjects: 91

Group type: COMPARATOR
Intervention: Radiotherapy for cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT)
Number of subjects: 91
Study: 32600386

Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: sham-rESWT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: standardised exercise programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups (including rESWT, sham-rESWT, standardised exercise, and usual care)
Number of subjects: 200
Study: 37450334

Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts with two response-efficacy messages and two self-efficacy messages
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts with self-efficacy messages
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Cigarette pack inserts
Number of subjects: 359
Study: 34080077

Group type: EXPERIMENTAL
Intervention: Oral danirixin 75 mg twice daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 32473084

Group type: EXPERIMENTAL
Intervention: Topical active lotion (Redensyl and Sepicontrol A5), applied twice daily for 24 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vehicle control, applied twice daily for 24 weeks
Number of subjects: 44
Study: 35662238

Group type: EXPERIMENTAL
Intervention: Reverse-fracture-prosthesis (RFP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Common reverse-prosthesis (RP)
Number of subjects: 44
Study: 32915514

Group type: EXPERIMENTAL
Intervention: Napping ≥5x/day at 1-month
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Each 1-hour increase in nocturnal sleep vs diurnal sleep
Number of subjects: 126
Study: 32415211

Group type: EXPERIMENTAL
Intervention: Opioids and pregabalin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Opioids only
Number of subjects: 39
Study: 35750501

Group type: EXPERIMENTAL
Intervention: Ceramic ultrathin occlusal veneers (e.max CAD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Composite resin ultrathin occlusal veneers (Lava Ultimate)
Number of subjects: 11
Study: 36269028

Group type: EXPERIMENTAL
Intervention: 5% lidocaine + 0.5 mg/ml 0.02% oestradiol compound cream + oral placebo pill
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant nortriptyline + placebo cream
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined peripheral cream and central pill treatments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream and placebo pill
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 100
Study: 34915854

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 71
Study: 33719918

Group type: EXPERIMENTAL
Intervention: High quality protein (30g/meal primarily from dairy) with caloric restriction (−500kcal/d) and low-intensity resistance exercise (30 min/3 times per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32920571

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no convalescent plasma)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Convalescent plasma from donors with high levels of SARS-CoV-2 IgG and positive SARS-CoV-2 IgM
Number of subjects: 49
Study: 35790976

Group type: EXPERIMENTAL
Intervention: PUFA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33622030

Group type: EXPERIMENTAL
Intervention: Audio Visual Distraction (AVD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 100
Study: 32819413

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 63
Study: 33150360

Group type: EXPERIMENTAL
Intervention: Truncated asparaginase treatment due to clinical toxicity (n = 358)
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Standard treatment without truncation (n = 1043)
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Truncated asparaginase treatment or silent inactivation (n = 301)
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Bone marrow relapse
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Central nervous system relapse
Number of subjects: 1401
Study: 35614156

Group type: EXPERIMENTAL
Intervention: Losartan ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 24
Study: 33651470

Group type: EXPERIMENTAL
Intervention: Water-soluble herbal acne patch (WHAP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hydrocolloid acne patch (HAP)
Number of subjects: 49
Study: 33182295

Group type: EXPERIMENTAL
Intervention: Pre-workout supplement
Number of subjects: 23
Study: 35864751

Group type: EXPERIMENTAL
Intervention: Cognitive Intervention (CI) - multifactorial training, 30 sessions
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group - standard activities
Number of subjects: 162
Study: 34288013

Group type: EXPERIMENTAL
Intervention: Tele-STELLA intervention (8-week videoconferencing components)
Number of subjects: 124
Study: 33725178

Group type: EXPERIMENTAL
Intervention: VC+ group (500 mg/day PO for 45 days postoperatively)
Number of subjects: 98

Group type: COMPARATOR
Intervention: VC- group (no supplementation)
Number of subjects: 98
Study: 33478521

Group type: EXPERIMENTAL
Intervention: pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine (PAG)
Number of subjects: 189
Study: 32299454

Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock wave lithotripsy (ESWL) and endoscopic treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined ESWL and endoscopic treatment
Number of subjects: 106
Study: 36027559

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg once daily)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 33124886

Group type: EXPERIMENTAL
Intervention: iNOS inhibition (0.1 mM 1400W)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (lactated Ringer)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: iNOS inhibition
Number of subjects: 40
Study: 32443298

Group type: EXPERIMENTAL
Intervention: low-dose recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: non-rt-PA (saline)
Number of subjects: 88
Study: 35232229

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 65
Study: 33338496

Group type: EXPERIMENTAL
Intervention: ezParent (digital delivery of the Chicago Parent Program)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Enhanced usual-care control
Number of subjects: 287
Study: 35818972

Group type: EXPERIMENTAL
Intervention: Nutrient-based recommendations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nutrient- and food-based recommendations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nutrient-, food- and food-substitution-based recommendations
Number of subjects: 240

Group type: COMPARATOR
Intervention: No recommendations (Control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nutrient-based, nutrient- and food-based, nutrient-, food- and food-substitution-based recommendations
Number of subjects: 240
Study: 34411158

Group type: EXPERIMENTAL
Intervention: Dabigatran 150mg
Number of subjects: 18040

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18040

Group type: EXPERIMENTAL
Intervention: Dabigatran 110mg
Number of subjects: 18040
Study: 33919800

Group type: EXPERIMENTAL
Intervention: Single LIST (1st LIST)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Three consecutive LISTs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Six consecutive LISTs
Number of subjects: 12
Study: 32174447

Group type: EXPERIMENTAL
Intervention: Positive comment intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative comment intervention
Number of subjects: 0
Study: 36277984

Group type: EXPERIMENTAL
Intervention: Anlotinib plus docetaxel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Anlotinib
Number of subjects: 84
Study: 34628881

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 48
Study: 35079761

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16 for 28 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16
Number of subjects: 103
Study: 34447866

Group type: EXPERIMENTAL
Intervention: Scissor knife
Number of subjects: 10
Study: 35490744

Group type: EXPERIMENTAL
Intervention: Lenabasum (20 mg daily for 28 days, then 20 mg twice per day for 56 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33332538

Group type: EXPERIMENTAL
Intervention: Individualized aerobic exercise program (B-FIT), 4-month duration, 2 low-intensity sessions and 1 high-intensity session per week
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Individualized aerobic exercise program (B-FIT)
Number of subjects: 31
Study: 35781692

Group type: COMPARATOR
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CMX)
Number of subjects: 60
Study: 33497465

Group type: EXPERIMENTAL
Intervention: Self-sampling (SS arm)
Number of subjects: 11951

Group type: COMPARATOR
Intervention: Sampling by medical professionals (SMP arm)
Number of subjects: 11951
Study: 32725069

Group type: EXPERIMENTAL
Intervention: Fungicide treatment FT1 (pyraclostrobin + fluxapyroxad)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fungicide treatment FT2 (trifloxystrobin + prothioconazole)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cultivar FM 975
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Shorter plants (1 m)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cultivar FM 944
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no fungicide)
Number of subjects: 4
Study: 34333889

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination (GSD) intervention with weekly sessions for eight weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (regular visits to the pain centre with doctors and nurses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination (GSD) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 32572779

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (pseudo-acupuncture)
Number of subjects: 76
Study: 35813843

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/b.m.)
Number of subjects: 13
Study: 33620417

Group type: EXPERIMENTAL
Intervention: Layperson-delivered, empathy-focused program of telephone calls
Number of subjects: 240

Group type: COMPARATOR
Intervention: No calls (control group)
Number of subjects: 240
Study: 32133542

Group type: EXPERIMENTAL
Intervention: Liman applications, bath, and heliotherapy (group 1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Mud-bath therapy using clay peloid mixed with tap water and heliotherapy (group 2)
Number of subjects: 91
Study: 35171145

Group type: EXPERIMENTAL
Intervention: Penetrating femtosecond laser corneal relaxing incisions (8 mm optical zone)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Intrastromal femtosecond laser corneal relaxing incisions (8 mm optical zone)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 9 mm penetrating femtosecond laser corneal relaxing incisions
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 248
Study: 34587106

Group type: EXPERIMENTAL
Intervention: One hand used for trajectory-tracking tasks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Other hand used for trajectory-tracking tasks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adaptation to reject disturbances (exogenously applied by the experimenter)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adaptation to reject disturbances (endogenously generated by sensorimotor noise)
Number of subjects: 18
Study: 32382043

Group type: EXPERIMENTAL
Intervention: SRI
Number of subjects: 182

Group type: COMPARATOR
Intervention: IUI
Number of subjects: 182
Study: 35538143

Group type: EXPERIMENTAL
Intervention: anthracycline/taxane‐based NACT plus metformin
Number of subjects: 80
Study: 32439227

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35725488

Group type: EXPERIMENTAL
Intervention: 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control (unvaccinated pregnant women)
Number of subjects: 2000
Study: 32178279

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil (12 g/day, EPA/DHA: 2.3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (12 g/day, EPA/DHA: 0.3)
Number of subjects: 30
Study: 35398293

Group type: EXPERIMENTAL
Intervention: Daily teriparatide (20 μg)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Weekly high-dose teriparatide (56.5 μg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Bisphosphonates (BPs)
Number of subjects: 131
Study: 32799967

Group type: EXPERIMENTAL
Intervention: GUMLi EAT FFQ
Number of subjects: 97
Study: 32495208

Group type: EXPERIMENTAL
Intervention: High density screw constructs (> 1.8 screws per level fused)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low density screw constructs (< 1.4 screws per level fused)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Understanding of the trial
Number of subjects: 159
Study: 35287618

Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid (TXA) 15 minutes before surgery
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo 15 minutes before surgery
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 33577729

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Chemotherapy (investigator-chosen standard docetaxel, paclitaxel, or vinflunine on day 1 of a 21-day cycle)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 608

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 608
Study: 34173699

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES) / Biolimus-eluting stents (BES)
Number of subjects: 240
Study: 32064967

Group type: EXPERIMENTAL
Intervention: Endometrial Myomectomy (EM)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Subserosal Myomectomy (SM)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 360
Study: 35691596

Group type: EXPERIMENTAL
Intervention: EGCG intervention
Number of subjects: 0
Study: 34215870

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 330

Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab and docetaxel
Number of subjects: 330
Study: 34989067

Group type: EXPERIMENTAL
Intervention: Messages about vaccination coverage rates (varied between 10% and 95%)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Messages about vaccination coverage rates (up to 75%)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Messages about vaccination coverage rates (above 75%)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Control group with no message
Number of subjects: 1365
Study: 33691075

Group type: EXPERIMENTAL
Intervention: EasyMICI–MaMICI® telemedicine platform
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 54
Study: 34898001

Group type: EXPERIMENTAL
Intervention: Nurse-led supportive-expressive group intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Health education and rehabilitation training (control group)
Number of subjects: 168
Study: 34446370

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 33382771

Group type: EXPERIMENTAL
Intervention: Protection routine 1 (Avoidance of the sun during peak hours, use of shade, UV-index awareness, planning activities)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Protection routine 2 (Increased use of hat and sunscreen application routine)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 1548
Study: 35947817

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 453

Group type: COMPARATOR
Intervention: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 453

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 453
Study: 33769420

Group type: EXPERIMENTAL
Intervention: Citizen responder activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citizen responder systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial of citizen responder activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0